PremiumCompany AnnouncementsViridian Therapeutics Appoints Jeff Ajer to Board Viridian Therapeutics appoints Ajer to its board of directors Viridian Therapeutics Enters New $300M Sale Agreement PremiumRatingsViridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating PremiumThe FlyViridian Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo Top 3 Trending Stocks, According to Analysts – 12/18/2024 Viridian Therapeutics price target raised to $47 from $44 at RBC Capital 
